Elevai Labs begins clinical study of topical exosome product

Elevai Labs announced the initiation of a clinical study to assess the efficacy of a topical exosome product in conjunction with an energy device treatment on facial skin appearance. The clinical study will assess the efficacy of Elevai’s topical exosomes Elevai empower, a topical exosome serum designed specifically for in-office application, and Elevai enfinity, a daily topical exosome product for at home use, as standalone treatments and in conjunction with an energy device treatment on facial skin appearance. The objective of the study is to investigate the efficacy of a topical exosome product on facial appearance after daily use for up to 12 weeks. Elevai is collaborating with Dr. Jennifer Pearlman, an internationally recognized leader in regenerative and aesthetic medicine, and Medical Director of the PearlMD Rejuvenation clinic in Toronto, Canada. The study will enroll up to 20 healthy subjects between the ages of 35-75 years of age of Fitzpatrick skin types I-VI with mild to moderate facial photoaging and sensitive skin, including those with acne, rosacea, pigmentation issues, eczema, atopic dermatitis, dry skin, or cosmetic intolerance syndrome. Endpoints will measure tolerability for absence of skin irritation, safety, and statistically significant improvement in overall facial appearance 12 weeks as compared to baseline.